Information Provided By:
Fly News Breaks for April 4, 2018
BIOC
Apr 4, 2018 | 11:03 EDT
WestPark Capital analyst Lauren Chung lowered her price target for Biocept to $1 following the company's Q4 results but maintains an Outperform rating on the name. While sales growth is slower than expected, Biocept continues to make "meaningful progress as an emerging pure play liquid biopsy diagnostics company," Chung tells investors in a post-earnings research note. Further, she views the Thermo Fisher collaboration as promising.
News For BIOC From the Last 2 Days
There are no results for your query BIOC